The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity

International Journal of Obesity

Volumn 39, Issue 1, 2015, Pages 130-135

  Belo, V A ^a   Luizon, M R ^a   Lacchini, R ^a   Miranda, J A ^b   Lanna, C M M ^c   Souza Costa, D C ^a   Tanus Santos, J E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

childhood obesity; haplotypes; metabolic risk factors; visfatin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ADOLESCENT; ARTICLE; BLOOD LEVEL; BODY MASS; CHILD; CHILDHOOD OBESITY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME IMMUNOASSAY; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NAMPT GENE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SCHOOL CHILD; WAIST CIRCUMFERENCE; BRAZIL; CARDIOVASCULAR DISEASE; GENETICS; METABOLISM; PATHOPHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; BODY MASS INDEX; BRAZIL; CARDIOVASCULAR DISEASES; CHILD; CYTOKINES; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PEDIATRIC OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 84920651026     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2013.173     Document Type: Article

References (48)

1. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2000; 11: 327-332.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
3. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-880.
4. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430.
5. Dahl TB, Holm S, Aukrust P, Halvorsen B. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu Rev Nutr 2012; 32: 229-243.
6. Saddi-Rosa P, Oliveira CS, Giuffrida FM, Reis AF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2010; 2: 21.
7. Dahl TB, Yndestad A, Skjelland M, Oie E, Dahl A, Michelsen A et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007; 115: 972-980.
8. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008; 78: 356-365.
9. Belo VA, Luizon MR, Carneiro PC, Gomes VA, Lacchini R, Lanna CM et al. Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity. Mol Biol Rep 2013; 40: 2697-2704.
10. Belo VA, Souza-Costa DC, Lana CM, Caputo FL, Marcaccini AM, Gerlach RF et al. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clin Biochem 2009; 42: 984-990.
11. Belo VA, Souza-Costa DC, Luizon MR, Lanna CM, Carneiro PC, Izidoro-Toledo TC et al. Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children. Int J Obes (Lond) 2012; 36: 69-75.
12. Belo VA, Souza-Costa DC, Luizon MR, Izidoro-Toledo TC, Lanna CM, Pinheiro LC et al. Vascular endothelial growth factor haplotypes associated with childhood obesity. DNA Cell Biol 2011; 30: 709-714.
13. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916.
14. Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O et al. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 2006; 43: 548-549.
15. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578-1581.
16. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011; 27: 515-527.
17. Krzystek-Korpacka M, Patryn E, Bednarz-Misa I, Hotowy K, Noczynska A. Visfatin in juvenile obesity-the effect of obesity intervention and sex. Eur J Clin Invest 2011; 41: 1284-1291.
18. Araki S, Dobashi K, Kubo K, Kawagoe R, Yamamoto Y, Kawada Y et al. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring) 2008; 16: 384-388.
19. Davutoglu M, Ozkaya M, Guler E, Garipardic M, Gursoy H, Karabiber H et al. Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices. Swiss Med Wkly 2009; 139: 22-27.
20. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6: 363-375.
21. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909-1914.
22. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, Recasens M, Esteve E, Casamitjana R et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55: 2871-2875.
23. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299.
24. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007; 76: 24-29.
25. Lan J, Chen X, Wang S, Zhang X, Wu K, He S et al. The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance. Diabetes Res Clin Pract 2011; 94: 71-76.
26. Bailey SD, Loredo-Osti JC, Lepage P, Faith J, Fontaine J, Desbiens KM et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 2006; 55: 2896-2902.
27. Gunes F, Akbal E, Cakir E, Akyurek O, Altunbas M, Ozbek M. Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients. Intern Med 2012; 51: 553-557.
28. Dogru T, Sonmez A, Tasci I, Yilmaz MI, Erdem G, Erturk H et al. Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J Hum Hypertens 2007; 21: 173-175.
29. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008; 69: 878-884.
30. Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, Koo TH et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 2008; 1783: 886-895.
31. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009; 71: 202-207.
32. Taskesen D, Kirel B, Us T. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol 2012; 4: 76-81.
33. Ooi SQ, Chan RM, Poh LK, Loke KY, Heng CK, Chan YH et al. Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children. Pediatr Obes 2014; 9: 81-91.
34. Crawford DC, Nickerson DA. Definition and clinical importance of haplotypes. Annu Rev Med 2005; 56: 303-320.
35. Leander K, Gigante B, Silveira A, Vikstrom M, Hamsten A, Hogberg J. NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction. Clin Chim Acta 2012; 413: 727-732.
36. Tabassum R, Mahendran Y, Dwivedi OP, Chauhan G, Ghosh S, Marwaha RK et al. Common variants of IL6, LEPR, and PBEF1 are associated with obesity in Indian children. Diabetes 2012; 61: 626-631.
37. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R et al. CDC growth charts: United States. Adv Data 2000; 8: 1-27.
38. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics 1996; 98: 649-658.
39. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003; 157: 821-827.
40. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350: 2362-2374.
41. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005; 115: e500-e503.
42. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
43. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989.
44. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-747.
45. Kolsgaard ML, Wangensteen T, Brunborg C, Joner G, Holven KB, Halvorsen B et al. Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome. Scand J Clin Lab Invest 2009; 69: 858-864.
46. Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 2008; 79: 412-418.
47. Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007; 92: 4783-4791.
48. Wang LS, Yan JJ, Tang NP, Zhu J, Wang YS, Wang QM et al. A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease. Mol Biol Rep 2010; 38: 819-825.